Join
Live feed
·
PRReleasevia Quantisnow
Traws Pharma Inc. logo

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

ByQuantisnow·Wall Street's wire, on your screen.
TRAW· Traws Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TRAW (Traws Pharma Inc.) and more on Quantisnow.